Formulation optimization of hot-melt extruded abuse deterrent pellet dosage form utilizing design of experiments
- 20 August 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 66 (2), 309-322
- https://doi.org/10.1111/jphp.12129
Abstract
Objective: The objective of this study was to develop techniques for an abuse-deterrent (AD) platform utilizing the hot-melt extrusion (HME) process. Methods: Formulation optimization was accomplished by utilizing Box–Behnken design of experiments to determine the effect of the three formulation factors: PolyOx WSR301, Benecel K15M and Carbopol 71G; each of which was studied at three levels on tamper-resistant (TR) attributes of the produced melt extruded pellets. A response surface methodology was utilized to identify the optimized formulation. Lidocaine hydrochloride was used as a model drug, and suitable formulation ingredients were employed as carrier matrices and processing aids. Key findings: All of the formulations were evaluated for the TR attributes, such as particle size post-milling, gelling and percentage of drug extraction in water and alcohol. All of the design of experiments formulations demonstrated sufficient hardness and elasticity, and could not be reduced into fine particles (<150 μm), which is a desirable feature to prevent snorting. In addition, all of the formulations exhibited good gelling tendency in water with minimal extraction of drug in the aqueous medium. Moreover, Benecel K15M, in combination with PolyOx WSR301, could be utilized to produce pellets with TR potential. Conclusion: HME has been demonstrated to be a viable technique with a potential to develop novel AD formulations.Keywords
Funding Information
- Pii Center for Pharmaceutical Technology and HRSA/OFAM/DGMO (#D1DHP20294)
- National Institute of General Medical Sciences (P20GM104931)
This publication has 22 references indexed in Scilit:
- Abuse risks and routes of administration of different prescription opioid compounds and formulationsHarm Reduction Journal, 2011
- Changes in time-use and drug use by young adults in poor neighbourhoods of Greater Buenos Aires, Argentina, after the political transitions of 2001-2002: Results of a surveyHarm Reduction Journal, 2011
- Update on Abuse-Resistant and Abuse-Deterrent Approaches to Opioid FormulationsPain Medicine, 2009
- Pharmaceutical Applications of Hot-Melt Extrusion: Part IIDrug Development and Industrial Pharmacy, 2007
- Influence of ethanol on aspirin release from hypromellose matricesInternational Journal of Pharmaceutics, 2006
- Extended-release opioids for the management of chronic non-malignant painExpert Opinion on Drug Delivery, 2006
- Ephemeral profiles of prescription drug and formulation tampering: Evolving pseudoscience on the InternetDrug and Alcohol Dependence, 2006
- Psychiatrie and Pain Characteristics of Prescription Drug Abusers Entering Drug RehabilitationJournal of Pain & Palliative Care Pharmacotherapy, 2006
- A Profile of OxyContin AddictionJournal of Addictive Diseases, 2004
- In vitro Release Kinetic Study of Theophylline from Eudragit RS PO and Eudragit RL PO Matrix TabletsDhaka University Journal of Pharmaceutical Sciences, 1970